Skip to main content

Oramed Pharmaceuticals Inc.

ORMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001176309

In the last 90 days, Oramed Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Oramed Pharmaceuticals Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of ORMP: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders47470
Shares7.25M9.21M+1.96M (+27.0%)
Value$16.3M$24.3M+$8.00M (+49.0%)

New holders (5)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to ORMP in Q3 2025
InstitutionSharesValue% of portfolio
Aquamarine Financial (Cayman) Ltd1,973,057$5.21M0.53%
XTX Topco Ltd23,885$63.1K0.00%
FMR LLC500$1.32K0.00%
JPMorgan Chase & Co170$4490.00%
Citigroup Inc4$110.00%

Sold out (5)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of ORMP in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Peapod Lane Capital LLC84,779$190.7K
State Street Corp66,451$149.5K
Raymond James Financial Inc3,576$8.05K
National Bank of Canada2,000$4.38K
Beacon Capital Management, LLC219$493